• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

Spark adds fresh ev­i­dence that pi­o­neer­ing gene ther­a­py could be a game chang­er for pa­tients

9 years ago
R&D

Bris­tol-My­ers reels back in an ear­ly-stage can­cer drug prospect in $60M Asia deal

9 years ago
R&D

Pro­to­cols: Valeant sheds as­sets, but falls short on con­sen­sus; What if vot­ers got a chance to weigh in on your tri­al?

9 years ago
News Briefing

As gene ther­a­py ri­vals ad­vance, Bio­gen moves clos­er to spin­ning out he­mo­phil­ia drugs, R&D

9 years ago
R&D

FDA clears a Phase III path for Bio­gen’s BACE drug for Alzheimer’s

9 years ago
R&D

Will Ab­b­Vie bite? De­ci­sion time af­ter Abl­ynx's rheuma­toid arthri­tis drug fails a key study

9 years ago
R&D

Now a two-time los­er, As­traZeneca’s hopes for selume­tinib dwin­dle af­ter an­oth­er PhI­II flop

9 years ago
R&D

Rac­ing past a wound­ed Juno, Kite aims to file lead CAR-T for OK by end of 2016

9 years ago
R&D

Pro­to­cols: Al­ler­gan diss­es gi­ant leaps, con­cen­trates on step­ping stones; As­traZeneca al­so gets a boost from ...

9 years ago
News Briefing

Acety­lon can say good­bye to buy­out and a $1B-plus in Cel­gene biobucks

9 years ago
R&D

No­var­tis's asth­ma ‘won­der drug’ basks in the bright spot­light of a UK me­dia fren­zy

9 years ago
R&D

Lit­tle MEI Phar­ma rock­ets up on $25M cash in­jec­tion, deep-pock­et part­ner for PhI­II AML can­cer study

9 years ago
R&D

Cel­gene stays fo­cused on pro­tein home­osta­sis, backs Cleave’s $37M round to fu­el ear­ly stud­ies

9 years ago
R&D

Al­ler­gan, Richter steer past an­oth­er late-stage pile­up with cariprazine

9 years ago
R&D

Pro­to­cols: Did Io­n­is set out to ex­clude side ef­fects? Mer­ck takes an­oth­er step for­ward with Lan­tus biosim­i­lar

9 years ago
News Briefing

Wood­ford gets slammed with a bru­tal set of port­fo­lio hits, as North­west con­tin­ues to fes­ter

9 years ago
R&D

Thumbs Up/Thumbs Down: The new buzz in R&D, block­buster work on a bud­get and why what’s dead may nev­er die

9 years ago
Bioregnum
Opinion

Bris­tol-My­ers craters af­ter block­buster check­point drug Op­di­vo fails key lung can­cer study

9 years ago
R&D

Gem­phire IPO stag­gers in­to the mar­ket, reap­ing $30M

9 years ago
R&D

Deaths de­rail Juno's launch count­down, giv­ing Kite and No­var­tis the lead

9 years ago
R&D

Pushed by high costs in Cam­bridge, fast-grow­ing Deci­bel makes a pi­o­neer­ing leap to Fen­way

9 years ago
R&D

Mo­men­ta hit with a set­back as pan­cre­at­ic can­cer drug flops in PhII

9 years ago
R&D

Re­gen­eron makes a block­buster case for its PhI­II drug pipeline

9 years ago
R&D

BioReg­num: What’s the deal with Bio­gen?

9 years ago
Bioregnum
Opinion
First page Previous page 1169117011711172117311741175 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times